Hong-Fang Ji1, Yan Sun2, Liang Shen3. 1. Shandong Provincial Research Center for Bioinformatic Engineering and Technique, Shandong University of Technology, Zibo, P. R. China. Electronic address: jhf@sdut.edu.cn. 2. Shandong Provincial Research Center for Bioinformatic Engineering and Technique, Shandong University of Technology, Zibo, P. R. China. 3. Shandong Provincial Research Center for Bioinformatic Engineering and Technique, Shandong University of Technology, Zibo, P. R. China. Electronic address: shen@sdut.edu.cn.
Abstract
OBJECTIVE: The antioxidant vitamin E has been extensively employed to treat chronic liver diseases. The aim of this study was to assess the effect of vitamin E supplementation in lowering alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in patients with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and chronic hepatitis C (CHC). METHODS: We searched all publications in PubMed, Web of Science, and Cochrane Library databases up to June 2013. In total, eight articles met the eligibility criteria, among which, two studies about NAFLD, four studies about NASH, and three studies about CHC, were identified and included in the meta-analysis. RESULTS: According to standardized mean difference and 95% confidence interval, 12.19 (-4.08 to 28.46) for ALT and 6.84 (-3.18 to 16.86) for AST in patients with NAFLD, 4.54 (1.62-7.46) for ALT and 3.55 (1.39-5.71) for AST in patients with NASH, and 0.61 (0.20-1.02) for ALT and 0.68 (0.07-1.29) for AST in patients with CHC, vitamin E supplementation could optimize ALT and AST levels in patients with NASH and CHC, although it was not statistically significantly associated with reduced ALT and AST levels in patients with NAFLD. CONCLUSION: To summarize, the evidence currently available supported the theory that vitamin E supplementation can optimize aminotransferase levels for patients with NAFLD, NASH, and CHC, and more well-designed, large-scale clinical trials are encouraged to examine the therapeutic effect of vitamin E for these disorders.
OBJECTIVE: The antioxidant vitamin E has been extensively employed to treat chronic liver diseases. The aim of this study was to assess the effect of vitamin E supplementation in lowering alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in patients with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and chronic hepatitis C (CHC). METHODS: We searched all publications in PubMed, Web of Science, and Cochrane Library databases up to June 2013. In total, eight articles met the eligibility criteria, among which, two studies about NAFLD, four studies about NASH, and three studies about CHC, were identified and included in the meta-analysis. RESULTS: According to standardized mean difference and 95% confidence interval, 12.19 (-4.08 to 28.46) for ALT and 6.84 (-3.18 to 16.86) for AST in patients with NAFLD, 4.54 (1.62-7.46) for ALT and 3.55 (1.39-5.71) for AST in patients with NASH, and 0.61 (0.20-1.02) for ALT and 0.68 (0.07-1.29) for AST in patients with CHC, vitamin E supplementation could optimize ALT and AST levels in patients with NASH and CHC, although it was not statistically significantly associated with reduced ALT and AST levels in patients with NAFLD. CONCLUSION: To summarize, the evidence currently available supported the theory that vitamin E supplementation can optimize aminotransferase levels for patients with NAFLD, NASH, and CHC, and more well-designed, large-scale clinical trials are encouraged to examine the therapeutic effect of vitamin E for these disorders.
Authors: Mathias Plauth; William Bernal; Srinivasan Dasarathy; Manuela Merli; Lindsay D Plank; Tatjana Schütz; Stephan C Bischoff Journal: Clin Nutr Date: 2019-01-16 Impact factor: 7.324
Authors: Gregory Guthrie; Madhulika Kulkarni; Hester Vlaardingerbroek; Barbara Stoll; Kenneth Ng; Camilia Martin; John Belmont; Darryl Hadsell; William Heird; Christopher B Newgard; Oluyinka Olutoye; Johannes van Goudoever; Charlotte Lauridsen; Xingxuan He; Edward H Schuchman; Douglas Burrin Journal: J Lipid Res Date: 2016-07-29 Impact factor: 5.922
Authors: Claudia P Oliveira; Priscila de Lima Sanches; Erlon Oliveira de Abreu-Silva; Aline Marcadenti Journal: J Diabetes Res Date: 2015-12-07 Impact factor: 4.011